Trial Overview

TRAILBLAZER-ALZ 3 is evaluating whether treatment with donanemab can slow the progression of Alzheimer’s disease. This randomized, double-blind, placebo-controlled trial enrolled cognitively unimpaired participants age 65-80 years of age with a blood test (p-tau) result consistent with the presence of amyloid and early-tau pathology.

Eli Lilly and Banner Alzheimer’s Institute formed a strategic research collaboration as part of the TRAILBLAZER-ALZ 3 program (clinicaltrials.gov NCT05026866). TRAILBLAZER-ALZ 3 is evaluating whether treatment with donanemab can slow the progression of Alzheimer’s disease. This randomized, double-blind, placebo-controlled trial enrolled cognitively unimpaired participants age 65-80 years of age with a blood test (p-tau) result consistent with the presence of amyloid and early-tau pathology. The TRAILBLAZER-ALZ 3 introduced a more virtual approach to the evaluation of Alzheimer’s prevention therapies by including “decentralized” trial sites and allowing participants and their study partners to complete many study procedures from home.